Approved by the Tianjin Medical Products Administration, ProteinT's independently developed plasma protein and polypeptide extraction or purification reagent was recently approved (Record No.: Jin Xie Bei 20230397), achieving a breakthrough detection of 6,000+ proteins from a single plasma sample.

Filing Certificate

Plasma is the most common body fluid for liquid biopsy and an ideal biological specimen for assessing human health and disease states, containing proteins secreted by almost all tissues in the human body. The plasma proteome has a wide dynamic range, with a concentration difference of more than 10 orders of magnitude between high-abundance albumin and low-abundance inflammatory factors. Its complexity and diversity provide rich material for the discovery of new biomarkers for liquid biopsy. How to remove high-abundance proteins and enrich more low-abundance proteins has become the biggest technical challenge.

Breaking the Bottleneck: A Technological Breakthrough in the Plasma Proteome

The independently developed protein, polypeptide, or purification extraction reagent approved by ProteinT this time uses nanomaterials to specifically adsorb plasma proteins, removing high-abundance proteins after elution to complete the extraction of the proteome. With only a trace amount of plasma sample, combined with the latest 4D mass spectrometry platform, it can achieve qualitative and quantitative analysis of up to 6,000+ proteins within a half-hour effective gradient from a single plasma sample, breaking through the bottleneck of plasma proteomics research.

Technical Highlights

This approval indicates that ProteinT's products have higher technological content and stronger safety, and is of great significance for the development and application of proteomics in vitro diagnostic products in the clinical field. In the future, ProteinT will continue to enhance its R&D and innovation capabilities and provide higher-quality products and services.